{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:54Z","timestamp":1787009394948,"version":"build-2736575974"},"reference-count":106,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1274501"],"award-info":[{"award-number":["24CDA1274501"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,20]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Amyloidosis is a group of complex diseases caused by the misfolding and aggregation of proteins into amyloid fibrils. Light-chain (AL) amyloidosis is one of the most prevalent forms of amyloidosis, characterized by the gradual proliferation of light chains from plasma cell clones. A growing body of evidence has contributed to our understanding of its pathogenesis, presentation and clinical course. Increased recognition of its clinical sequelae has increased the prevalence of AL amyloidosis. Renal involvement, seen in up to 70% of cases, is particularly challenging due to its impact on quality of life and access to treatment options. Thus, early recognition of its unique sequelae, appropriate staging and a comprehensive understanding of treatment options balanced by their organ toxicities are crucial to managing this disease. We review the current treatment standards and discuss novel developments in the pathophysiology, diagnosis, outcome prediction and management of AL amyloidosis for the Nephrologist.<\/jats:p>","DOI":"10.1093\/ndt\/gfae224","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:24:33Z","timestamp":1728055473000},"page":"34-47","source":"Crossref","is-referenced-by-count":6,"title":["Light-chain (AL) amyloidosis for nephrologists\u2014treatment standard"],"prefix":"10.1093","volume":"40","author":[{"given":"Shankara","family":"Anand","sequence":"first","affiliation":[{"name":"Department of Medicine, Amyloidosis Center; Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center , Boston, MA ,","place":["USA"]},{"name":"Department of Medicine, Stanford School of Medicine , Stanford, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"O'Neill-Dee","sequence":"additional","affiliation":[{"name":"Department of Medicine, Amyloidosis Center; Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center , Boston, MA ,","place":["USA"]},{"name":"Department of Medicine, Massachusetts General Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[{"name":"Department of Medicine, Amyloidosis Center; Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Amyloidosis Center; Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center , Boston, MA ,","place":["USA"]},{"name":"Section of Nephrology, Department of Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"2026041420121308400_bib1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"2026041420121308400_bib2","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"key":"2026041420121308400_bib3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"2026041420121308400_bib4","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2157581","article-title":"Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis","volume":"28","author":"Kastritis","year":"2023","journal-title":"Hematology"},{"key":"2026041420121308400_bib5","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.amjmed.2022.01.011","article-title":"Update on the Contemporary treatment of light chain amyloidosis including stem cell transplantation","volume":"135","author":"Abdallah","year":"2022","journal-title":"Am J Med"},{"key":"2026041420121308400_bib6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib7","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.1681\/ASN.2006050460","article-title":"Amyloidosis-associated kidney disease","volume":"17","author":"Dember","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026041420121308400_bib8","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.2169\/internalmedicine.54.5174","article-title":"Rapid deterioration of the renal function caused by the coexistence of intratubular amyloidosis and myeloma cast nephropathy","volume":"54","author":"Kato","year":"2015","journal-title":"Intern Med"},{"key":"2026041420121308400_bib9","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.2215\/CJN.12551214","article-title":"Leukocyte cell-derived chemotaxin 2-associated amyloidosis: a recently recognized disease with distinct clinicopathologic characteristics","volume":"10","author":"Nasr","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026041420121308400_bib10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.kint.2016.04.003","article-title":"Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis","volume":"90","author":"Dasari","year":"2016","journal-title":"Kidney Int"},{"key":"2026041420121308400_bib11","doi-asserted-by":"crossref","first-page":"532","DOI":"10.5858\/134.4.532","article-title":"A proposed histopathologic classification, scoring, and grading system for renal amyloidosis: standardization of renal amyloid biopsy report","volume":"134","author":"Sen","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"2026041420121308400_bib12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1080\/13506129.2017.1360272","article-title":"Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis","volume":"24","author":"Rubinstein","year":"2017","journal-title":"Amyloid"},{"key":"2026041420121308400_bib13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/ckj\/sfaa019","article-title":"Renal amyloidosis: validation of a proposed histological scoring system in an independent cohort","volume":"14","author":"Hoelbeek","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026041420121308400_bib14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","article-title":"Amyloidosis","volume":"57","author":"Pepys","year":"2006","journal-title":"Annu Rev Med"},{"key":"2026041420121308400_bib15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"107","author":"Oubari","year":"2021","journal-title":"Eur J Haematol"},{"key":"2026041420121308400_bib16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bbapap.2005.08.014","article-title":"Clinical aspects of systemic amyloid diseases","volume":"1753","author":"Obici","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"2026041420121308400_bib17","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.amjmed.2022.01.003","article-title":"Renal amyloidosis: presentation, diagnosis, and management","volume":"135","author":"Gurung","year":"2022","journal-title":"Am J Med"},{"key":"2026041420121308400_bib18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/clc.22353","article-title":"Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis","volume":"38","author":"Cappelli","year":"2015","journal-title":"Clin Cardiol"},{"key":"2026041420121308400_bib19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/0046-8177(91)90180-W","article-title":"Hepatic amyloidosis: morphologic differences between systemic AL and AA types","volume":"22","author":"Buck","year":"1991","journal-title":"Hum Pathol"},{"key":"2026041420121308400_bib20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","article-title":"Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients","volume":"82","author":"Park","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"2026041420121308400_bib21","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/13506129.2011.574354030","article-title":"Approach to diagnosis in systemic amyloidosis: initial findings and time from symptoms onset to diagnosis (light-chain amyloidosis vs. transthyretin). Problems and observations","volume":"18","author":"Di Girolamo","year":"2011","journal-title":"Amyloid"},{"key":"2026041420121308400_bib22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ajh.21603","article-title":"Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients","volume":"85","author":"Thompson","year":"2010","journal-title":"Am J Hematol"},{"key":"2026041420121308400_bib23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1182\/blood-2017-09-807560","article-title":"How I manage monoclonal gammopathy of undetermined significance","volume":"131","author":"Go","year":"2018","journal-title":"Blood"},{"key":"2026041420121308400_bib24","first-page":"1760","article-title":"Biomarker-based screening of organ dysfunction in patients with MGUS allows early diagnosis of AL amyloidosis","volume":"130","author":"Palladini","year":"2017","journal-title":"Blood"},{"key":"2026041420121308400_bib25","doi-asserted-by":"publisher","first-page":"100427","DOI":"10.1016\/j.xkme.2022.100427","article-title":"Correlation between 24-hour urine protein and random urine protein-creatinine ratio in amyloid light-chain amyloidosis","volume":"4","author":"Mendelson","year":"2022","journal-title":"Kidney Med"},{"key":"2026041420121308400_bib26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41408-019-0180-1","article-title":"A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis","volume":"9","author":"Sharpley","year":"2019","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib28","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"2026041420121308400_bib29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1053\/j.ajkd.2008.05.022","article-title":"Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients","volume":"52","author":"Soares","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026041420121308400_bib31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-319-19294-9_15","article-title":"Thioflavin T stain: an easier and more sensitive method for amyloid detection","volume-title":"Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations","author":"Picken","year":"2015"},{"key":"2026041420121308400_bib32","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","article-title":"Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics","volume":"99","author":"Vrana","year":"2014","journal-title":"Haematologica"},{"key":"2026041420121308400_bib33","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026041420121308400_bib34","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"2026041420121308400_bib35","first-page":"220","article-title":"Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival","volume":"109","author":"Oubari","year":"2024","journal-title":"Haematologica"},{"key":"2026041420121308400_bib36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026041420121308400_bib37","first-page":"215","article-title":"Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis","volume-title":"Blood","author":"Lilleness","year":"2019"},{"key":"2026041420121308400_bib38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1182\/blood-2023-178243","article-title":"Limited utility of Mayo 2012 cardiac staging system for risk stratification of patients with advanced cardiac AL amyloidosis\u2014analysis of a uniformly treated cohort of 1275 patients","volume":"142","author":"Khwaja","year":"2023","journal-title":"Blood"},{"key":"2026041420121308400_bib39","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"2026041420121308400_bib40","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ajh.24738","article-title":"Renal outcomes in patients with AL amyloidosis: prognostic factors, renal response and the impact of therapy","volume":"92","author":"Kastritis","year":"2017","journal-title":"Am J Hematol"},{"key":"2026041420121308400_bib41","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1515\/cclm-2021-0912","article-title":"Prospective urinary albumin\/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients","volume":"60","author":"Basset","year":"2022","journal-title":"Clin Chem Lab Med"},{"key":"2026041420121308400_bib42","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.ekir.2024.03.033","article-title":"Renal response criteria for clinical trials in amyloid light chain amyloidosis","volume":"9","author":"Leung","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026041420121308400_bib43","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2021-149594","article-title":"Graded renal response criteria for light chain (AL) amyloidosis","volume":"138","author":"Muchtar","year":"2021","journal-title":"Blood"},{"key":"2026041420121308400_bib44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026041420121308400_bib45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026041420121308400_bib46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2026041420121308400_bib47","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026041420121308400_bib48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2022.2093635","article-title":"Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group","volume":"30","author":"Wechalekar","year":"2023","journal-title":"Amyloid"},{"key":"2026041420121308400_bib49","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1097\/HS9.0000000000000681","article-title":"Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis","volume":"6","author":"Sanchorawala","year":"2022","journal-title":"HemaSphere"},{"key":"2026041420121308400_bib50","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","article-title":"Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis","volume":"103","author":"Manwani","year":"2018","journal-title":"Haematologica"},{"key":"2026041420121308400_bib51","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"key":"2026041420121308400_bib52","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","article-title":"Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis","volume":"8","author":"Kastritis","year":"2018","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib53","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-021-00428-0","article-title":"Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis","volume":"11","author":"Palladini","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib54","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1182\/blood.2023022399","article-title":"Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis","volume":"143","author":"Bomsztyk","year":"2024","journal-title":"Blood"},{"key":"2026041420121308400_bib55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2141.2007.06783.x","article-title":"Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone \u00b1 thalidomide for systemic light-chain amyloidosis: results of a phase II trial","volume":"139","author":"Cohen","year":"2007","journal-title":"Br J Haematol"},{"key":"2026041420121308400_bib56","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/leu.2012.274","article-title":"Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis","volume":"27","author":"Landau","year":"2013","journal-title":"Leukemia"},{"key":"2026041420121308400_bib57","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ajh.25572","article-title":"Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis","volume":"94","author":"Al Saleh","year":"2019","journal-title":"Am J Hematol"},{"key":"2026041420121308400_bib58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"29","author":"Sanchorawala","year":"2022","journal-title":"Amyloid"},{"key":"2026041420121308400_bib59","doi-asserted-by":"publisher","first-page":"3778","DOI":"10.3390\/jcm9113778","article-title":"AL amyloidosis: the effect of maintenance therapy on autologous stem cell transplantation outcomes","volume":"9","author":"Ozga","year":"2020","journal-title":"J Clin Med"},{"key":"2026041420121308400_bib60","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41409-019-0524-2","article-title":"Autologous stem cell transplantation in patients with AL amyloidosis with impaired renal function","volume":"54","author":"Sidiqi","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"2026041420121308400_bib61","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1093\/ndt\/gfv328","article-title":"The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation","volume":"31","author":"Leung","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2026041420121308400_bib62","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"37","author":"Nader","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026041420121308400_bib63","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ejca.2017.02.004","article-title":"Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis","volume":"76","author":"Le Bras","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026041420121308400_bib64","doi-asserted-by":"publisher","first-page":"2730","DOI":"10.1182\/blood-2021-152540","article-title":"Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: a phase 2 study by the European Myeloma Network","volume":"138","author":"Kastritis","year":"2021","journal-title":"Blood"},{"key":"2026041420121308400_bib65","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000506760","article-title":"Supportive care in AL amyloidosis","volume":"143","author":"Cibeira","year":"2020","journal-title":"Acta Haematol"},{"key":"2026041420121308400_bib66","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.kint.2018.09.021","article-title":"Long-term outcome of kidney transplantation in AL amyloidosis","volume":"95","author":"Angel-Korman","year":"2019","journal-title":"Kidney Int"},{"key":"2026041420121308400_bib67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-022-00714-5","article-title":"Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through the International Kidney and Monoclonal Gammopathy Research Group","volume":"12","author":"Havasi","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026041420121308400_bib68","doi-asserted-by":"publisher","first-page":"151496","DOI":"10.1016\/j.semnephrol.2024.151496","article-title":"Systemic amyloidosis and kidney transplantation: an update","volume":"44","author":"Anand","year":"2024","journal-title":"Semin Nephrol"},{"key":"2026041420121308400_bib69","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1111\/ajt.15487","article-title":"Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis","volume":"19","author":"Trachtenberg","year":"2019","journal-title":"Am J Transplant"},{"key":"2026041420121308400_bib70","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1055\/s-0039-1688994","article-title":"Neuropathy associated with systemic amyloidosis","volume":"39","author":"Kaku","year":"2019","journal-title":"Semin Neurol"},{"key":"2026041420121308400_bib71","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13256-020-02405-w","article-title":"Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report","volume":"14","author":"Ho","year":"2020","journal-title":"J Med Case Rep"},{"key":"2026041420121308400_bib72","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","article-title":"When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression","volume":"3","author":"Palladini","year":"2019","journal-title":"Blood Adv"},{"key":"2026041420121308400_bib73","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1080\/13506129.2020.1765768","article-title":"Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed\/refractory AL amyloidosis","volume":"27","author":"Cohen","year":"2020","journal-title":"Amyloid"},{"key":"2026041420121308400_bib74","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"key":"2026041420121308400_bib75","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1080\/10428194.2020.1802452","article-title":"Daratumumab, lenalidomide, and dexamethasone combination in relapsed\/refractory myeloma patients: a real-life single-center experience","volume":"61","author":"Antonioli","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"2026041420121308400_bib76","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","article-title":"A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis","volume":"130","author":"Sanchorawala","year":"2017","journal-title":"Blood"},{"key":"2026041420121308400_bib77","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/bjh.16401","article-title":"Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis","volume":"189","author":"Cohen","year":"2020","journal-title":"Br J Haematol"},{"key":"2026041420121308400_bib78","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41375-021-01317-y","article-title":"A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis","volume":"36","author":"Dispenzieri","year":"2022","journal-title":"Leukemia"},{"key":"2026041420121308400_bib79","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1182\/blood.V128.22.645.645","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"128","author":"Cohen","year":"2016","journal-title":"Blood"},{"key":"2026041420121308400_bib80","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.critrevonc.2016.01.004","article-title":"Immunomodulatory drugs in AL amyloidosis","volume":"99","author":"Jelinek","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026041420121308400_bib81","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","article-title":"A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis","volume":"119","author":"Kastritis","year":"2012","journal-title":"Blood"},{"key":"2026041420121308400_bib82","doi-asserted-by":"publisher","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","article-title":"Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"2026041420121308400_bib83","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/13506129.2020.1767566","article-title":"Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients","volume":"27","author":"Milani","year":"2020","journal-title":"Amyloid"},{"key":"2026041420121308400_bib84","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1200\/JCO.2014.57.4947","article-title":"Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens","volume":"33","author":"Bochtler","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026041420121308400_bib85","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers15061710","article-title":"Venetoclax in relapse\/refractory AL amyloidosis\u2014a multicenter international retrospective real-world study","volume":"15","author":"Lebel","year":"2023","journal-title":"Cancers"},{"key":"2026041420121308400_bib86","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/01.HS9.0000936096.74708.86","article-title":"B01 Venetoclax targeted therapy in AL amyloidosis patients: a retrospective analysis from the French amyloidosis network","volume":"7","author":"Roussel","year":"2023","journal-title":"HemaSphere"},{"key":"2026041420121308400_bib87","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood.2023022937","article-title":"Teclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"key":"2026041420121308400_bib88","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1200\/JCO.19.01721","article-title":"Bendamustine with dexamethasone in relapsed\/refractory systemic light-chain amyloidosis: results of a phase II study","volume":"38","author":"Lentzsch","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026041420121308400_bib89","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2023-175005","article-title":"Blood-based diagnostic assay for \u03bb light chain amyloidosis through quantification of an amyloidogenicity-indicating neo-epitope","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"2026041420121308400_bib90","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody\u2013drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026041420121308400_bib91","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1182\/blood-2023-173317","article-title":"Belantamab mafodotin in relapse\/refractory AL amyloidosis- real-life multi-center experience","volume":"142","author":"Lebel","year":"2023","journal-title":"Blood"},{"key":"2026041420121308400_bib92","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.clml.2018.08.021","article-title":"Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma","volume":"19","author":"Iqbal","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041420121308400_bib93","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/S2152-2650(24)01004-8","article-title":"Updated OS of patients with AL amyloidosis after CAEL","volume":"24","author":"Hughes","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026041420121308400_bib94","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"2026041420121308400_bib95","doi-asserted-by":"publisher","first-page":"19960","DOI":"10.1038\/s41598-019-56498-5","article-title":"C. elegans expressing D76N \u03b22-microglobulin: a model for in vivo screening of drug candidates targeting amyloidosis","volume":"9","author":"Faravelli","year":"2019","journal-title":"Sci Rep"},{"key":"2026041420121308400_bib96","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","article-title":"Doxycycline combined with bortezomib-cyclophosphamide-dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial","volume":"145","author":"Shen","year":"2022","journal-title":"Circulation"},{"key":"2026041420121308400_bib97","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"2026041420121308400_bib98","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"key":"2026041420121308400_bib99","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"key":"2026041420121308400_bib100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","article-title":"Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis","volume":"28","author":"Palladini","year":"2021","journal-title":"Amyloid"},{"key":"2026041420121308400_bib101","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","article-title":"Graded cardiac response criteria for patients with systemic light chain amyloidosis","volume":"41","author":"Muchtar","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041420121308400_bib102","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1182\/blood-2015-08-662726","article-title":"Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience","volume":"126","author":"Sanchorawala","year":"2015","journal-title":"Blood"},{"key":"2026041420121308400_bib103","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bbmt.2017.08.031","article-title":"High-dose melphalan and stem cell transplantation in patients on dialysis due to immunoglobulin light-chain amyloidosis and monoclonal immunoglobulin deposition disease","volume":"24","author":"Batalini","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041420121308400_bib104","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ndt\/gfs492","article-title":"End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases","volume":"28","author":"Tang","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2026041420121308400_bib105","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2215\/CJN.02470607","article-title":"Presentation and outcome of patients with systemic amyloidosis undergoing dialysis","volume":"3","author":"Boll\u00e9e","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026041420121308400_bib106","first-page":"81","article-title":"Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy","volume":"38","author":"Moroni","year":"1992","journal-title":"Clin Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfae224\/60734705\/gfae224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/1\/34\/60734705\/gfae224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/1\/34\/60734705\/gfae224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:20:27Z","timestamp":1776212427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/1\/34\/7815202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":106,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,7]]},"published-print":{"date-parts":[[2024,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae224","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,7]]}}}